ERBB2 and breast neoplasm: An additional study [259] revealed that a triple combination of neratinib plus a CDK4/6 inhibitor plus endocrine therapy was more efficient in reducing proliferation and colony formation in HR-positive/HER2-low breast tumor cells (ZR-75-1) than CDK4/6 inhibitor plus endocrine therapy alone.